These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33998411)

  • 41. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.
    Widiarti W; Sukmajaya AC; Nugraha D; Alkaff FF
    Diabetes Metab Syndr; 2021; 15(3):837-843. PubMed ID: 33866119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glucagon-like peptide-1 receptor agonists for improving cardiorenal outcomes in type 1 diabetes mellitus?
    Popovic DS; Stoian AP; Papanas N
    Endocrine; 2023 Apr; 80(1):232-233. PubMed ID: 36607508
    [No Abstract]   [Full Text] [Related]  

  • 45. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. GLP-1 Receptor Agonists for Cardiovascular Protection: A Matter of Time.
    Caruso I; Cignarelli A; Laviola L; Giorgino F
    Diabetes Care; 2022 Feb; 45(2):e30-e31. PubMed ID: 35020816
    [No Abstract]   [Full Text] [Related]  

  • 47. [Semaglutide for the Management of type 2 Diabetes: Clinical Evidence, Cardioprotective Effects, and Guidelines].
    Kobalava ZD; Kokhan EV
    Kardiologiia; 2020 Oct; 60(9):122-133. PubMed ID: 33131483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
    Kim MK; Kim DM
    J Diabetes Investig; 2021 Jun; 12(6):914-916. PubMed ID: 33759351
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular Safety of Glucagon-Like Receptor 1 Agonists in Patients With Type 2 Diabetes and Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials.
    Ashraf MT; Ali A; Ahmed N; Shakeel Khan MK; Usman M
    Am J Ther; 2024 Jul-Aug 01; 31(4):e483-e486. PubMed ID: 38976535
    [No Abstract]   [Full Text] [Related]  

  • 50. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The year in cardiovascular medicine 2021: diabetes and metabolic disorders.
    Cosentino F; Bhatt DL; Marx N; Verma S
    Eur Heart J; 2022 Jan; 43(4):263-270. PubMed ID: 34974614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor.
    Helmstädter J; Keppeler K; Küster L; Münzel T; Daiber A; Steven S
    Br J Pharmacol; 2022 Feb; 179(4):659-676. PubMed ID: 33764504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New Insights into Cardiovascular Diseases Treatment Based on Molecular Targets.
    Wojtasińska A; Kućmierz J; Tokarek J; Dybiec J; Rodzeń A; Młynarska E; Rysz J; Franczyk B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Making sense of newer treatment options for type 2 diabetes.
    Lee PC; Hare MJL; Bach LA
    Intern Med J; 2018 Jul; 48(7):762-769. PubMed ID: 29984503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.
    Lingvay I; Leiter LA
    Circulation; 2018 May; 137(21):2200-2202. PubMed ID: 29784677
    [No Abstract]   [Full Text] [Related]  

  • 59. The effect of glucagon-like peptide 1 on cardiovascular risk.
    Sivertsen J; Rosenmeier J; Holst JJ; Vilsbøll T
    Nat Rev Cardiol; 2012 Jan; 9(4):209-22. PubMed ID: 22290234
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.
    Marchand L; Luyton C; Bernard A
    Diabet Med; 2021 Jan; 38(1):e14390. PubMed ID: 32799379
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.